Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NYSE:BHVN NASDAQ:KOD NASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.05-2.2%$2.90$2.56▼$6.44$593.13M0.254.34 million shs2.99 million shsBHVNBiohaven$15.60-7.1%$11.89$7.48▼$18.57$2.35B1.282.71 million shs2.13 million shsKODKodiak Sciences$41.31+3.1%$36.91$4.32▼$47.84$2.59B2.19914,858 shs996,375 shsNTLAIntellia Therapeutics$14.22-7.9%$14.37$7.95▼$28.25$1.99B1.775.65 million shs6.16 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+0.32%-1.27%+17.29%-3.70%-34.18%BHVNBiohaven+0.14%+5.09%+50.68%+82.42%+15.85%KODKodiak Sciences-1.35%+4.00%+29.04%-7.03%+802.70%NTLAIntellia Therapeutics-8.31%-12.07%+19.78%+14.46%+27.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.05-2.2%$2.90$2.56▼$6.44$593.13M0.254.34 million shs2.99 million shsBHVNBiohaven$15.60-7.1%$11.89$7.48▼$18.57$2.35B1.282.71 million shs2.13 million shsKODKodiak Sciences$41.31+3.1%$36.91$4.32▼$47.84$2.59B2.19914,858 shs996,375 shsNTLAIntellia Therapeutics$14.22-7.9%$14.37$7.95▼$28.25$1.99B1.775.65 million shs6.16 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+0.32%-1.27%+17.29%-3.70%-34.18%BHVNBiohaven+0.14%+5.09%+50.68%+82.42%+15.85%KODKodiak Sciences-1.35%+4.00%+29.04%-7.03%+802.70%NTLAIntellia Therapeutics-8.31%-12.07%+19.78%+14.46%+27.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.70Moderate Buy$15.71415.22% UpsideBHVNBiohaven 2.67Moderate Buy$21.6338.64% UpsideKODKodiak Sciences 2.63Moderate Buy$42.142.02% UpsideNTLAIntellia Therapeutics 2.35Hold$20.6745.39% UpsideCurrent Analyst Ratings BreakdownLatest ALT, NTLA, KOD, and BHVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2026NTLAIntellia Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$12.00 ➝ $17.006/29/2026BHVNBiohaven Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.006/29/2026BHVNBiohaven Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$12.00 ➝ $11.006/26/2026BHVNBiohaven Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/24/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/22/2026ALTAltimmune Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.006/16/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$49.006/15/2026NTLAIntellia Therapeutics New Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$25.006/15/2026NTLAIntellia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/15/2026NTLAIntellia Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/15/2026NTLAIntellia Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$12.00(Data available from 7/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$40K14,828.34N/AN/A$1.99 per share1.53BHVNBiohavenN/AN/AN/AN/A$0.39 per shareN/AKODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/ANTLAIntellia Therapeutics$67.67M29.36N/AN/A$5.80 per share2.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)BHVNBiohaven-$738.82M-$5.67N/AN/AN/AN/A-866.46%-137.99%8/10/2026 (Estimated)KODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)NTLAIntellia Therapeutics-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)Latest ALT, NTLA, KOD, and BHVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026NTLAIntellia Therapeutics-$0.80N/AN/AN/A$12.98 millionN/A5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/11/2026Q1 2026NTLAIntellia Therapeutics-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A5/4/2026Q1 2026BHVNBiohaven-$0.86-$0.88-$0.02-$0.88$0.27 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56BHVNBiohaven1.877.417.41KODKodiak SciencesN/A3.543.54NTLAIntellia TherapeuticsN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%BHVNBiohaven88.78%KODKodiak Sciences89.06%NTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%BHVNBiohaven13.80%KODKodiak Sciences45.90%NTLAIntellia Therapeutics3.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionableBHVNBiohaven239150.56 million129.78 millionOptionableKODKodiak Sciences9062.58 million33.86 millionOptionableNTLAIntellia Therapeutics600139.72 million134.83 millionOptionableALT, NTLA, KOD, and BHVN HeadlinesRecent News About These CompaniesWedbush Raises Intellia Therapeutics (NASDAQ:NTLA) Price Target to $17.00July 10 at 8:47 AM | marketbeat.comY Intercept Hong Kong Ltd Buys New Shares in Intellia Therapeutics, Inc. $NTLAJuly 10 at 6:31 AM | marketbeat.comIntellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z SuccessJuly 9 at 3:14 PM | finance.yahoo.comNTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?July 9 at 11:21 AM | zacks.comIntellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On ReturnsJuly 9 at 10:13 AM | finance.yahoo.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of "Hold" by AnalystsJuly 9 at 4:13 AM | marketbeat.comA new CRISPR DNA shredder could change gene-editing -- what it means for CRISPR TherapeuticsJuly 8 at 7:58 AM | msn.comA new CRISPR DNA shredder could change gene-editing -- what it means for CRISPR TherapeuticsJuly 8 at 7:58 AM | msn.comIntellia Therapeutics (NASDAQ:NTLA) CAO Michael Dube Sells 2,641 SharesJuly 7 at 10:33 AM | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) CAO Sells 2,641 Shares of StockJuly 7 at 9:52 AM | insidertrades.comIntellia Therapeutics (NASDAQ:NTLA) EVP Edward Dulac III Sells 4,677 SharesJuly 7 at 9:46 AM | americanbankingnews.comIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | globenewswire.comIs Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now?July 3, 2026 | insidermonkey.comMost shorted stocks over $2B market capJuly 1, 2026 | seekingalpha.comIntellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?June 20, 2026 | fool.comAnalysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA)June 17, 2026 | theglobeandmail.comNTLA Posts Strong Additional Phase III Data From HAE Study, Stock UpJune 16, 2026 | zacks.comStrength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?June 16, 2026 | zacks.comIntellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling DisorderJune 15, 2026 | benzinga.comWhy is NTLA stock jumping 5% premarket today?June 15, 2026 | msn.comPositive Phase III results for Intellia’s lonvo-zJune 15, 2026 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhat to Expect From Q2 Earnings as Tech Strength BroadensBy Thomas Hughes | June 14, 2026SpaceX Valuation Loses Altitude as AI Risks MountBy Jeffrey Neal Johnson | June 23, 2026Flying Under the Radar: Lockheed Martin's $2.8B Stealth SetupBy Jeffrey Neal Johnson | June 17, 2026Beyond the AI Trade: 3 Defensive Stocks Built for StabilityBy Thomas Hughes | June 20, 2026Cerebras Systems, Inc: The Next Rags-to-Riches AI Story?By Thomas Hughes | June 25, 2026ALT, NTLA, KOD, and BHVN Company DescriptionsAltimmune NASDAQ:ALT$3.05 -0.07 (-2.24%) Closing price 04:00 PM EasternExtended Trading$3.04 -0.01 (-0.49%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Biohaven NYSE:BHVN$15.60 -1.19 (-7.10%) Closing price 03:59 PM EasternExtended Trading$15.54 -0.06 (-0.37%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Kodiak Sciences NASDAQ:KOD$41.31 +1.23 (+3.07%) Closing price 04:00 PM EasternExtended Trading$42.17 +0.86 (+2.09%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Intellia Therapeutics NASDAQ:NTLA$14.22 -1.22 (-7.90%) Closing price 04:00 PM EasternExtended Trading$14.18 -0.04 (-0.32%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab’s Stock Drop Comes With a Bullish Twist Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth PepsiCo’s Dividend Could Turn Patience Into Real Profit Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
